SAA1 Knockdown Promotes the Apoptosis of Glioblastoma Cells Via Downregulation of AKT Signaling

Overview

Journal J Cancer

Specialty Oncology

Date 2021 Apr 15

PMID 33854635

Citations 8

Authors

Huikai Zhang

Yang Xu

Gang Deng

Fanen Yuan

Yinqiu Tan

Lun Gao

Qian Sun

Yangzhi Qi

Kun Yang

Rongxin Geng

Hongxiang Jiang

Baohui Liu

Qianxue Chen

Affiliations

Soon will be listed here.

Abstract

Serum amyloid A1 (SAA1) is an inflammatory associated high-density lipoprotein. And It is also considered as a predictor and prognostic marker of cancer risk. However, its role and mechanisms in glioblastoma (GBM) still unclear. In this study, we validate that SAA1 is up-regulated in GBM, and its high expression predicts poor prognosis. SAA1 knockdown promotes the apoptosis of GBM cell. Mechanistically, SAA1 knockdown can inhibit serine/threonine protein kinase B (AKT) phosphorylation, thereby regulating the expression of apoptosis-related proteins such as Bcl2 and Bax, leading to GBM cell death. Moreover, Gliomas with low SAA1 expression have increased sensitivity to Temozolomide (TMZ). Low SAA1 expression segregated glioma patients who were treated with Temozolomide (TMZ) or with high MGMT promoter methylation into survival groups in TCGA and CGGA dataset. Our study strongly suggested that SAA1 was a regulator of cells apoptosis and acted not only as a prognostic marker but also a novel biomarker of sensitivity of glioma to TMZ.

Citing Articles

Using Multi-Omics Analysis to Explore Diagnostic Tool and Optimize Drug Therapy Selection for Patients with Glioma Based on Cross-Talk Gene Signature.

Yang Y, Hu C, Lei S, Bao X, Zeng Z, Cao W Oncol Res. 2024; 32(12):1921-1934.

PMID: 39574472 PMC: 11576925. DOI: 10.32604/or.2024.046191.

Gene expression profiling and the isocitrate dehydrogenase mutational landscape of temozolomide‑resistant glioblastoma.

Chen W, Chuang J, Yang S, Chen N, Bhattacharya M, Liu H Oncol Lett. 2024; 28(2):378.

PMID: 38939621 PMC: 11209862. DOI: 10.3892/ol.2024.14511.

SAA1 regulated by S1P/S1PR1 promotes the progression of ESCC via β-catenin activation.

Li Q, Tang M, Zhao S, Yang J, Meng Y, Meng C Discov Oncol. 2024; 15(1):66.

PMID: 38446289 PMC: 10917729. DOI: 10.1007/s12672-024-00923-3.

New insights into the role of adipocytes in pancreatic cancer progression: paving the way towards novel therapeutic targets.

Lin Y, Hou Y, Wang H, Shan Y Theranostics. 2023; 13(12):3925-3942.

PMID: 37554282 PMC: 10405844. DOI: 10.7150/thno.82911.

SAA1 Expression as a Potential Prognostic Marker of the Tumor Microenvironment in Glioblastoma.

Cao K, Jiang X, Wang B, Ni Z, Chen Y Front Neurol. 2022; 13:905561.

PMID: 35756918 PMC: 9226422. DOI: 10.3389/fneur.2022.905561.

References

Christenson K, Bjorkman L, Tangemo C, Bylund J . Serum amyloid A inhibits apoptosis of human neutrophils via a P2X7-sensitive pathway independent of formyl peptide receptor-like 1. J Leukoc Biol. 2007; 83(1):139-48. DOI: 10.1189/jlb.0507276. View

He R, Sang H, Ye R . Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/LXA4R. Blood. 2002; 101(4):1572-81. DOI: 10.1182/blood-2002-05-1431. View

Louis D, Ohgaki H, Wiestler O, Cavenee W, Burger P, Jouvet A . The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007; 114(2):97-109. PMC: 1929165. DOI: 10.1007/s00401-007-0243-4. View

Milan E, Lazzari C, Anand S, Floriani I, Torri V, Sorlini C . SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. J Proteomics. 2012; 76 Spec No.:91-101. DOI: 10.1016/j.jprot.2012.06.022. View

Scheid M, Woodgett J . Unravelling the activation mechanisms of protein kinase B/Akt. FEBS Lett. 2003; 546(1):108-12. DOI: 10.1016/s0014-5793(03)00562-3. View

Xie X, Ma Y, Yang Y, Li X, Zheng Y, Liu F . Genetic polymorphisms of serum amyloid A1 and coronary artery disease risk. Tissue Antigens. 2015; 85(3):168-76. DOI: 10.1111/tan.12516. View

Lin C, Yang S, Shen S, Hsieh Y, Hsu F, Chen C . Serum amyloid A1 in combination with integrin αVβ3 increases glioblastoma cells mobility and progression. Mol Oncol. 2018; 12(5):756-771. PMC: 5928363. DOI: 10.1002/1878-0261.12196. View

Lee H, Kim M, Park K, Bae Y, Yun J, Park J . Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem Biophys Res Commun. 2005; 330(3):989-98. DOI: 10.1016/j.bbrc.2005.03.069. View

Conus N, Hannan K, Cristiano B, Hemmings B, Pearson R . Direct identification of tyrosine 474 as a regulatory phosphorylation site for the Akt protein kinase. J Biol Chem. 2002; 277(41):38021-8. DOI: 10.1074/jbc.M203387200. View

10.

Urieli-Shoval S, Linke R, Matzner Y . Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol. 1999; 7(1):64-9. DOI: 10.1097/00062752-200001000-00012. View

11.

Cho W, Yip T, Cheng W, Au J . Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer. 2010; 102(12):1731-5. PMC: 2883701. DOI: 10.1038/sj.bjc.6605700. View

12.

Sarbassov D, Guertin D, Ali S, Sabatini D . Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005; 307(5712):1098-101. DOI: 10.1126/science.1106148. View

13.

Eyupoglu I, Buchfelder M, Savaskan N . Surgical resection of malignant gliomas-role in optimizing patient outcome. Nat Rev Neurol. 2013; 9(3):141-51. DOI: 10.1038/nrneurol.2012.279. View

14.

Wang J, Zheng Y, Yang J, Lin Y, Dai S, Zhang G . Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer. 2012; 12:365. PMC: 3492207. DOI: 10.1186/1471-2407-12-365. View

15.

Li R, Chen X, You Y, Wang X, Liu Y, Hu Q . Comprehensive portrait of recurrent glioblastoma multiforme in molecular and clinical characteristics. Oncotarget. 2015; 6(31):30968-74. PMC: 4741581. DOI: 10.18632/oncotarget.5038. View

16.

Ye R, Sun L . Emerging functions of serum amyloid A in inflammation. J Leukoc Biol. 2015; 98(6):923-9. PMC: 6608020. DOI: 10.1189/jlb.3VMR0315-080R. View

17.

Cocco E, Bellone S, El-Sahwi K, Cargnelutti M, Buza N, Tavassoli F . Serum amyloid A: a novel biomarker for endometrial cancer. Cancer. 2009; 116(4):843-51. PMC: 2819580. DOI: 10.1002/cncr.24838. View

18.

Liang J, Sloane J, Wells J, Abraham C, Fine R, Sipe J . Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci Lett. 1997; 225(2):73-6. DOI: 10.1016/s0304-3940(97)00196-1. View

19.

El Kebir D, Jozsef L, Khreiss T, Pan W, Petasis N, Serhan C . Aspirin-triggered lipoxins override the apoptosis-delaying action of serum amyloid A in human neutrophils: a novel mechanism for resolution of inflammation. J Immunol. 2007; 179(1):616-22. DOI: 10.4049/jimmunol.179.1.616. View

20.

Badolato R, Johnston J, Wang J, McVicar D, Xu L, Oppenheim J . Serum amyloid A induces calcium mobilization and chemotaxis of human monocytes by activating a pertussis toxin-sensitive signaling pathway. J Immunol. 1995; 155(8):4004-10. View